Rituximab
Monoclonal Antibody
DB00073
Approved Indication
For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
12
Targets
0
Resistance Mutations
5
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.
Details
DrugBank ID
DB00073 ↗
Approval Date
1997-11-26
Molecular Weight
— g/mol
Drug Class
Monoclonal Antibody
ATC Codes
L01XC02
Synonyms
AntiCD20
ChEMBL
CHEMBL1201576 ↗
Drug References (DrugBank)